COMMUNIQUÉS West-GlobeNewswire

Sanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)
06/10/2025
Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history. Q3 2025 revenue increased [...]
Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million
06/10/2025
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION [...]
BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
06/10/2025
MELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced [...]
EssilorLuxottica: Third-Quarter 2025 Revenue Conference Call Invitation
06/10/2025
Third-Quarter 2025 Revenue Conference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our Third-Quarter 2025 Revenue [...]
EssilorLuxottica: Third-Quarter 2025 Revenue Conference Call Invitation
06/10/2025
Third-Quarter 2025 Revenue Conference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our Third-Quarter 2025 Revenue [...]
PharmaCielo Completes La Margarita Land Sale, Repays Banco Agrario Loan, Strengthens Balance Sheet, Completes Audit
06/10/2025
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ All amounts expressed in Canadian dollars unless otherwise noted TORONTO and RIONEGRO, Colombia, Oct. 06, 2025 (GLOBE [...]
BPGbio Appoints Veteran Clinical and Commercial Leader Dr. Brian Berman as Interim Chief Medical Officer
06/10/2025
Company strengthens its late-stage trials with enhanced clinical and commercial leadership for its BPM31510 programs Dr. Berman is a renowned scientist and clinical leader with a passion and track record in [...]
Pharming Group provides update on previously announced G&A expense reduction plan
06/10/2025
Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company [...]
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates
06/10/2025
New debt facility extends repayment from Q1 2026 to Q4 2030, lowers interest rate and provides access to additional capital for future business development Company adjusts 2025 financial guidance and provides key [...]
Valneva consolide sa position de trésorerie en refinançant sa dette auprès de Pharmakon Advisors et fait un point sur ses activités
06/10/2025
Le nouvel accord de prêt diffère le remboursement de la dette du premier trimestre 2026 au quatrième trimestre 2030, à un taux d’intérêt inférieur au précédent, et offre la possibilité d’obtenir davantage de financement [...]
Arcadia Medicine Announces FDA Clearance of IND Application for a Patented Form of MDMA
06/10/2025
SAN FRANCISCO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Arcadia Medicine (‘Arcadia’), a company developing safer empathogens to treat mental health disorders, has announced that the United States Food and Drug Administration ( [...]
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms
06/10/2025
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that three posters featuring new and previously reported analyses from its Phase [...]
MMI Completes World’s First Robotic Microsurgical Intracranial Brain Surgery
06/10/2025
First-in-human cases lay the foundation for the next frontier in robotic microsurgery JACKSONVILLE, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MMI (Medical Microinstruments, Inc.), a robotics company dedicated to expanding [...]
Cuprina to Present Live, Answer Questions, at Skyline Signature Series™ on October 8th, 2025, at 11:00 AM ET
06/10/2025
Individual and institutional investors, advisors, and analysts are invited to attend SINGAPORE, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited ( Nasdaq: CUPR ) (“ Cuprina ” or “ the Company ”), a [...]
Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025
06/10/2025
October 6, 2025 Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX [...]
GATC Health’s Derisq™ AI Report Introduced at Invitation-Only Webinar Hosted by ASTR Partners
06/10/2025
Biotech, pharma and finance leaders attend “Rethinking Risk – How AI Can Optimize Biotech Capital Allocation” IRVINE, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- GATC Health Corp, a leading tech-bio company leveraging [...]
Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments
06/10/2025
JUPITER, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing [...]
NewGen Reports Total Gain from IP Acquisition of $17.9 Million for FY 2025
06/10/2025
Valuation Report from Big Four Global Accounting Firm Sets Fair Value of Acquired IP at US$17.9 Million and Boosts NAV per share by about US$8.9 Acquisition Will Aid NewGen’s Transition From IVF Services Provider to [...]
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
06/10/2025
Ra’anana, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C [...]

Pages